AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

July 18, 2018

Study Completion Date

January 28, 2019

Conditions
Wounded WarriorLimb ShorteningAmputation
Interventions
DEVICE

Enhanced Fat Grafting

"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."

PROCEDURE

Standard fat graft

Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

All Listed Sponsors
lead

J. Peter Rubin, MD

OTHER

NCT02076022 - AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized | Biotech Hunter | Biotech Hunter